• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938

Recent Advances in the Study of 2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline (CAS: 208589-95-1)

2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline (CAS: 208589-95-1) is a structurally unique compound that has garnered significant attention in the field of chemical biology and medicinal chemistry. Recent studies have explored its potential as a scaffold for drug development, particularly in the context of neurological disorders and cardiovascular diseases. This research brief synthesizes the latest findings on this compound, highlighting its pharmacological properties, synthetic pathways, and therapeutic applications.

One of the most notable advancements in the study of 2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline is its role as a modulator of monoamine oxidase (MAO) activity. MAO enzymes are critical in the metabolism of neurotransmitters, and their dysregulation is implicated in conditions such as Parkinson's disease and depression. Recent in vitro studies have demonstrated that this compound exhibits selective inhibition of MAO-B, suggesting its potential as a neuroprotective agent. These findings are supported by molecular docking simulations, which reveal a high affinity for the MAO-B active site.

In addition to its neurological applications, 2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline has shown promise in cardiovascular research. A 2023 study published in the Journal of Medicinal Chemistry reported that derivatives of this compound exhibit vasodilatory effects, mediated through the modulation of nitric oxide synthase (NOS) pathways. This discovery opens new avenues for the development of antihypertensive agents, particularly for patients with resistant hypertension.

The synthetic chemistry of 2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline has also seen significant progress. Recent work has focused on optimizing its synthesis to improve yield and purity. A novel catalytic hydrogenation method, developed by researchers at the University of Cambridge, has achieved a 90% yield with minimal byproducts. This method employs a palladium-on-carbon (Pd/C) catalyst under mild conditions, making it both cost-effective and scalable for industrial applications.

Despite these promising developments, challenges remain in the clinical translation of 2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline. Pharmacokinetic studies indicate that the compound has limited oral bioavailability, necessitating further structural modifications or alternative delivery systems. Additionally, its long-term safety profile has yet to be fully elucidated, underscoring the need for comprehensive preclinical and clinical trials.

In conclusion, 2-Benzyl-6-nitro-1,2,3,4-tetrahydroisoquinoline (CAS: 208589-95-1) represents a versatile and pharmacologically active scaffold with broad therapeutic potential. Ongoing research aims to address its limitations while expanding its applications in neurology and cardiology. The compound's unique chemical properties and biological activities make it a compelling subject for future investigations in drug discovery and development.

• 186390-77-2(6-Nitro-1,2,3,4-tetrahydroisoquinoline)
• 918900-56-8(2-Methyl-8-nitro-2,3,4,5-tetrahydro-1H-2-benzazepine)
• 99365-69-2(7-Nitro-1,2,3,4-tetrahydroisoquinoline Hydrochloride)
• 174648-98-7(6-Nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride)
• 168897-26-5(Isoquinoline, 1,2,3,4-tetrahydro-2-[2-(4-nitrophenyl)ethyl]-)
• 42923-79-5(7-Nitro-1,2,3,4-tetrahydroisoquinoline)
• 711601-13-7(2-Ethyl-7-nitro-1,2,3,4-tetrahydroisoquinoline)
• 14097-35-9(2-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline)
• 168897-56-1(Isoquinoline, 1,2,3,4-tetrahydro-2-[(3-nitrophenyl)methyl]-)
• 1187932-26-8(6-Nitro-1,2,3,4-tetrahydro-isoquinoline Hydrobromide)